Comparative Positron-Emission Tomography (PET) Imaging and Phototherapeutic Potential of 124I- Labeled Methyl- 3-(1′-iodobenzyloxyethyl)pyropheophorbide-a vs the Corresponding

详细信息    查看全文

• 作者：Suresh K. Pandey ; Munawwar Sajjad ; Yihui Chen ; Xiang Zheng ; Rutao Yao ; Joseph R. Missert ; Carrie Batt ; Hani A. Nabi ; Allan R. Oseroff ; Ravindra K. Pandey
• 刊名：Journal of Medicinal Chemistry
• 出版年：2009
• 出版时间：January 22, 2009
• 年：2009
• 卷：52
• 期：2
• 页码：445-455
• 全文大小：310K
• 年卷期：v.52,no.2(January 22, 2009)
• ISSN：1520-4804

文摘

In our present study, 3-(1^′-m-iodobenzyloxyethyl)pyropheophorbide-a methyl ester 1, 3-(1′-m-iodobenzyloxyethyl)-17²-{(2-deoxy)glucose}pyropheophorbide-a 2, and 3-(1′-m-iodobenzyloxyethyl)-17²-{(1-deoxy)galactose}pyropheophorbide-a 3 were synthesized and converted into the corresponding ¹²⁴I-labeled analogues by reacting the intermediate trimethyltin analogues with Na¹²⁴I. Photosensitizers 1−3 were evaluated for the PDT efficacy in C3H mice bearing RIF tumors at variable doses and showed a significant long-term tumor cure. Among the compounds investigated, the non-carbohydrate analogue 1 was most effective. These results were in contrast to the in vitro data, where compared to the parent analogue the corresponding galactose and glucose derivatives showed enhanced cell kill. Among the corresponding ¹²⁴I-labeled analogues, excellent tumor images were obtained from compound 1 in both tumor models (RIF and Colon-26) and the best tumor contrast was observed at 72 h after injection. Conjugating a glucose moiety to photosensitizer 1 initially diminished its tumor uptake, whereas with time the corresponding galactose analogue showed improved tumor contrast.